ArticlePloS one2012
Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Cardiac progenitor cell therapy: mechanisms of action.Cell & bioscience · 2024Review
- A susceptibility biomarker identification strategy based on significantly differentially expressed ceRNA triplets for ischemic cardiomyopathy.Bioscience reports · 2020Article
- Review
- Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells Are Functionally and Genetically Different From Bone Marrow-Derived Mesenchymal Stromal Cells.Stem cells (Dayton, Ohio) · 2019Article
- Establishment of A Protocol for In Vitro Culture of Cardiogenic Mesodermal Cells Derived from Human Embryonic Stem Cells.Cell journal · 2019Article
- Advances in Regenerative Medicine and Tissue Engineering: Innovation and Transformation of Medicine.Stem cells international · 2018Review
- Article
- Irx4 Marks a Multipotent, Ventricular-Specific Progenitor Cell.Stem cells (Dayton, Ohio) · 2016Article
- Thermosensitive and Highly Flexible Hydrogels Capable of Stimulating Cardiac Differentiation of Cardiosphere-Derived Cells under Static and Dynamic Mechanical Training Conditions.ACS applied materials & interfaces · 2016Article
- p300/β-Catenin Interactions Regulate Adult Progenitor Cell Differentiation Downstream of WNT5a/Protein Kinase C (PKC).The Journal of biological chemistry · 2016Article
- Non-invasive Chamber-Specific Identification of Cardiomyocytes in Differentiating Pluripotent Stem Cells.Stem cell reports · 2016Article
- Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.Stem cells translational medicine · 2016Article
- Improving Cell Engraftment in Cardiac Stem Cell Therapy.Stem cells international · 2016Review
- Antifibrotic therapies to control cardiac fibrosis.Biomaterials research · 2016Review
- Are we closer to cardiac regeneration?Stem cell investigation · 2016Article
- Proceedings: Moving Toward Cell-Based Therapies for Heart Disease.Stem cells translational medicine · 2015Article
- Biomaterial Approaches for Stem Cell-Based Myocardial Tissue Engineering.Biomarker insights · 2015Review
- Regenerative medicine for the heart: perspectives on stem-cell therapy.Antioxidants & redox signaling · 2014Review
- Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine.Journal of cardiovascular pharmacology and therapeutics · 2014Article
- Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation.PloS one · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundCardiovascular progenitor cells (CPCs) have been identified within the developing mouse heart and differentiating pluripotent stem cells by intracellular transcription factors Nkx2.5 and Islet 1 (Isl1). Study of endogenous and induced pluripotent stem cell (iPSC)-derived CPCs has been limited due to the lack of specific cell surface markers to isolate them and conditions for their in vitro expansion that maintain their multipotency. METHODOLOGY/PRINCIPAL
findingsWe sought to identify specific cell surface markers that label endogenous embryonic CPCs and validated these markers in iPSC-derived Isl1(+)/Nkx2.5(+) CPCs. We developed conditions that allow propagation and characterization of endogenous and iPSC-derived Isl1(+)/Nkx2.5(+) CPCs and protocols for their clonal expansion in vitro and transplantation in vivo. Transcriptome analysis of CPCs from differentiating mouse embryonic stem cells identified a panel of surface markers. Comparison of these markers as well as previously described surface markers revealed the combination of Flt1(+)/Flt4(+) best identified and facilitated enrichment for Isl1(+)/Nkx2.5(+) CPCs from embryonic hearts and differentiating iPSCs. Endogenous mouse and iPSC-derived Flt1(+)/Flt4(+) CPCs differentiated into all three cardiovascular lineages in vitro. Flt1(+)/Flt4(+) CPCs transplanted into left ventricles demonstrated robust engraftment and differentiation into mature cardiomyocytes (CMs). CONCLUSION/SIGNIFICANCE: The cell surface marker combination of Flt1 and Flt4 specifically identify and enrich for an endogenous and iPSC-derived Isl1(+)/Nkx2.5(+) CPC with trilineage cardiovascular potential in vitro and robust ability for engraftment and differentiation into morphologically and electrophysiologically mature adult CMs in vivo post transplantation into adult hearts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.